Gastroparesis Treatment Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2030

The report on the global gastroparesis treatment market provides qualitative and quantitative analysis for the period from 2021-2030. The global gastroparesis treatment market was valued at USD 8.20 billion in 2022 and is expected to reach USD 11.09 billion in 2030, with a CAGR of 3.30% during the forecast period 2023-2030. The study on gastroparesis treatment market covers the analysis of the leading geographies such as North America, Europe, Asia Pacific, and RoW for the period of 2021-2030.

Gastroparesis, known as delayed gastric emptying, arises from damage to the vagus nerve and abnormal stomach and intestinal muscle function, with diabetes frequently as the primary trigger due to nerve and vascular damage from high blood glucose levels. Gastroparesis Treatment aims to alleviate symptoms and improve nutrition. Medications like Metoclopramide (Reglan), Erythromycin, and Domperidone help stimulate stomach emptiness and alleviate nausea and vomiting. In certain cases, physicians recommend Jejunostomy tube feeding to provide essential nutrients and calories, offering extended nutritional support over oral or nasal tube feeding. Parenteral nutrition, delivering nutrients directly into the bloodstream, is an alternative to Jejunostomy tubes and aids during difficult gastroparesis periods. Furthermore, a gastric neurostimulator, surgically implanted, eases nausea and vomiting by emitting mild electrical pulses, especially beneficial for gastroparesis linked to vagus nerve damage. For some patients, pyloroplasty, a procedure widening and relaxing the pyloric valve, accelerates stomach emptying, providing relief from gastroparesis symptoms.

Gastroparesis most commonly results from diabetes; wherein high blood glucose levels cause nerve chemical alterations and harm to blood vessels supplying nerves with oxygen and nutrients. In addition to diabetes, there is a condition known as Idiopathic Gastroparesis (IG). IG is caused due to several factors such as nerve damage, muscle problems, or other medical conditions, such as scleroderma, amyloidosis, and lupus. IG is a persistent ailment affecting stomach muscle movement-controlling nerves, thus there is a prerequisite need for effective gastroparesis treatment. This treatment encompasses dietary adjustments, insulin, oral medications, and, in severe cases, the use of feeding tubes and parenteral nutrition to enhance stomach emptying and regain control of blood glucose levels. As a result, the rising prevalence of diabetes and idiopathic gastroparesis in the population is driving the expansion of the gastroparesis treatment market. Moreover, the elderly population's susceptibility to gastroparesis is heightened by factors like inefficient oral medication absorption, impaired appetite regulation, and post-meal blood sugar fluctuations. Consequently, the increasing elderly demographic grappling with gastrointestinal problems is fueling the demand for gastroparesis treatments. However, side effects of gastroparesis drugs include fatigue, nausea, vomiting, sleepiness, depression, anxiety, and problems with physical movement such as abdominal cramps. Therefore, the occurrence of side effects during treatment may restrict the growth potential of the gastroparesis treatment market. Although, personalized treatment approaches have the potential to mitigate the impact of side effects, making treatments more tolerable for patients. Therefore, embracing personalized treatment approaches in the field of gastroparesis creates an opportunity for companies to customize more effective therapies.

North America boasts the largest market share in the gastroparesis treatment market for several key reasons. The region's advanced healthcare infrastructure and robust research and development initiatives foster innovation in treatment options. Furthermore, the region's well-developed reimbursement systems and insurance coverage enhance patient access to treatment, increasing market demand. Additionally, a high prevalence of gastroparesis cases in North America, often associated with conditions like diabetes and post-surgical complications, drives the demand for effective therapies. The growing aging population prone to gastroparesis and an increasing focus on healthcare technologies contribute to North America's dominant position in the Gastroparesis treatment market, as it continues to lead in terms of market size and influence. Asia Pacific's rapid urbanization and economic growth have made it the fastest-growing market for Gastroparesis treatment. This trend is exemplified by real-world cases, such as the increased prevalence of gastroparesis in India due to shifting dietary habits, with 77 million adults aged 18 and above dealing with diabetes-related gastroparesis. Consequently, there is a rising demand for Gastroparesis treatment in the Asia Pacific region. Additionally, pharmaceutical companies are expanding their presence in Asia Pacific, offering innovative treatments.

Report Findings

1) Drivers

• The rising prevalence of diabetes and idiopathic gastroparesis in the population is fueling the expansion of the gastroparesis market.
• A rising elderly population experiencing gastrointestinal issues driving demand for gastroparesis treatments.

2) Restraints

• The occurrence of side effects during treatment may restrict the growth potential of the gastroparesis treatment market.

3) Opportunities

• Embracing personalized treatment approaches in the field of gastroparesis creates an opportunity for companies to customize more effective therapies.

Research Methodology

A) Primary Research

The primary research involves extensive interviews and analysis of the opinions provided by the primary respondents. The primary research starts with identifying and approaching the primary respondents.

The primary respondents approached include:

1. Key Opinion Leaders
2. Internal and External subject matter experts
3. Professionals and participants from the industry

The primary research respondents typically include:

1. Executives working with leading companies in the market under review
2. Product/brand/marketing managers
3. CXO level executives
4. Regional/zonal/country managers
5. Vice President level executives.

B) Secondary Research

Secondary research involves extensive exploring through the secondary sources of information available in both the public domain and paid sources. Each research study is based on over 500 hours of secondary research accompanied by primary research. The information obtained through the secondary sources is validated through the crosscheck on various data sources.

The secondary sources of the data typically include:

1. Company reports and publications
2. Government/institutional publications
3. Trade and associations journals
4. Databases such as WTO, OECD, World Bank, and among others.
5. Websites and publications by research agencies

Segments Covered

The global gastroparesis treatment market is segmented on the basis of type, drug class, treatment, and distribution channel.

The Global Gastroparesis Treatment Market by Type

• Diabetic
• Idiopathic
• Post-surgical
• Others

The Global Gastroparesis Treatment Market by Drug Class

• Prokinetic Drugs
• Antiemetics
• Botulinum Toxin Injection
• Antidepressants
• Others

The Global Gastroparesis Treatment Market by Treatment

• Jejunostomy
• Gastric Electric Stimulation
• Parenteral Nutrition
• Diabetic Gastroparesis
• Post-operative Gastroparesis
• Others

The Global Gastroparesis Treatment Market by Distribution Channel

• Retail Pharmacies
• Hospital Pharmacies
• Others

Company Profiles

The companies covered in the report include:

• Medtronic
• Neurogastrx, Inc.
• Endologic
• Takeda Pharmaceutical Company Limited
• Theravance Biopharma
• EVOKE PHARMA
• Cedars-Sinai
• GSK plc
• CinDome Pharma, Inc.
• Processa Pharmaceuticals, Inc.

What does this Report Deliver?

1. Comprehensive analysis of the global as well as regional markets of the gastroparesis treatment market.

2. Complete coverage of all the segments in the gastroparesis treatment market to analyze the trends, developments in the global market and forecast of market size up to 2030.

3. Comprehensive analysis of the companies operating in the global gastroparesis treatment market. The company profile includes analysis of product portfolio, revenue, SWOT analysis and latest developments of the company.

4. The Growth Matrix presents an analysis of the product segments and geographies that market players should focus to invest, consolidate, expand and/or diversify.